Plasma Levels of K18 Fragments Do Not Correlate with Alcoholic Liver Fibrosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Noninvasive markers of liver fibrosis in alcoholic liver disease (ALD) are crucial to establish early intervention. Previous studies have suggested that plasma levels of cleaved keratin-18 (K18; M30) fragments can predict the severity of liver disease. The aim of this study was to correlate plasma M30 levels with stages of liver fibrosis in ALD. Methods: Patients with ALD (n=139, 79.1% males) and liver histology were included, and plasma samples were collected to quantify plasma M30 levels. Patients were stratified into five groups by fibrosis stage (F0=14; F1=15; F2=35; F3=17; and F4=58) according to the Kleiner score. Differences between groups were evaluated using the chi-square test or analysis of variance. Trends by fibrosis stage were calculated by logistic regression analysis, and sensitivity, specificity and positive and negative predictive values were determined. Results: There were no significant differences in M30 levels among fibrosis stages. The correlation between plasma M30 levels and fibrosis was poor (Pearson’s correlation coefficient= 0.13, Spearman rho=0.20 [p=0.02]), and M30 levels did not correlate with alcohol-specific histological features. However, significant correlations of M30 levels with aspartate aminotransferase (Spearman rho=0.653, p<0.001) and alanine aminotransferase (Spearman rho=0.432, p<0.001) were found. M30 levels of >200 U/L reveal a sensitivity for predicting cirrhosis of 84.5% with a negative predictive value of 73.5%. Conclusions: Plasma M30 levels are often elevated in ALD and correlate with serum transaminases but do not reflect fibrosis. The usefulness as a prognostic marker awaits evaluation in prospective studies.
Abstract
Background/Aims: Noninvasive markers of liver fibrosis in alcoholic liver disease (ALD) are crucial to establish early intervention. Previous studies have suggested that plasma levels of cleaved keratin-18 (K18; M30) fragments can predict the severity of liver disease. The aim of this study was to correlate plasma M30 levels with stages of liver fibrosis in ALD. Methods: Patients with ALD (n=139, 79.1% males) and liver histology were included, and plasma samples were collected to quantify plasma M30 levels. Patients were stratified into five groups by fibrosis stage (F0=14; F1=15; F2=35; F3=17; and F4=58) according to the Kleiner score. Differences between groups were evaluated using the chi-square test or analysis of variance. Trends by fibrosis stage were calculated by logistic regression analysis, and sensitivity, specificity and positive and negative predictive values were determined. Results: There were no significant differences in M30 levels among fibrosis stages. The correlation between plasma M30 levels and fibrosis was poor (Pearson’s correlation coefficient= 0.13, Spearman rho=0.20 [p=0.02]), and M30 levels did not correlate with alcohol-specific histological features. However, significant correlations of M30 levels with aspartate aminotransferase (Spearman rho=0.653, p<0.001) and alanine aminotransferase (Spearman rho=0.432, p<0.001) were found. M30 levels of >200 U/L reveal a sensitivity for predicting cirrhosis of 84.5% with a negative predictive value of 73.5%. Conclusions: Plasma M30 levels are often elevated in ALD and correlate with serum transaminases but do not reflect fibrosis. The usefulness as a prognostic marker awaits evaluation in prospective studies.
참고문헌 (27)
- Felix Stickel, "Pathophysiology and Management of Alcoholic Liver Disease: Update 2016", Gut and Liver, 11(2), pp.173~188 (2017), 거트앤리버 소화기연관학회협의회
- Teli MR, "Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver", Lancet, 346, pp.987~990 (1995)
- Kamper-Jørgensen M, "Alcohol and cirrhosis : dose--response or threshold effect?", J Hepatol, 41, pp.25~30 (2004)
- Rehm J, "Alcohol as a risk factor for liver cirrhosis : a systematic review and meta-analysis", Drug Alcohol Rev, 29, pp.437~445 (2010)
- Bedossa P, "Sampling variability of liver fibrosis in chronic hepatitis C", Hepatology, 38, pp.1449~1457 (2003)
- Cadranel JF, "Practices of liver biopsy in France:results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF)", Hepatology, 32, pp.477~481 (2000)
- Chrostek L, "Liver fibrosis markers in alcoholic liver disease", World J Gastroenterol, 20, pp.8018~8023 (2014)
- Nguyen-Khac E, "Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan : prospective comparison with seven non-invasive laboratory tests", Aliment Pharmacol Ther, 28, pp.1188~1198 (2008)
- Mueller S, "Increased liver stiffness in alcoholic liver disease : differentiating fibrosis from steatohepatitis", World J Gastroenterol, 16, pp.966~972 (2010)
- Feldstein AE, "Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis : a multicenter validation study", Hepatology, 50, pp.1072~1078 (2009)
- Joka D, "Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis", Hepatology, 55, pp.455~464 (2012)
- Kramer G, "Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18", Cancer Res, 64, pp.1751~1756 (2004)
- Cusi K, "Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease", J Hepatol, 60, pp.167~174 (2014)
- Kwok R, "Systematic review with metaanalysis : non-invasive assessment of non-alcoholic fatty liver disease : the role of transient elastography and plasma cytokeratin-18fragments", Aliment Pharmacol Ther, 39, pp.254~269 (2014)
- Mueller S, "Caspase-cleaved keratin-18fragments increase during alcohol withdrawal and predict liverrelated death in patients with alcoholic liver disease", Hepatology, 66, pp.96~107 (2017)
- Mathurin P, "Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features", Aliment Pharmacol Ther, 25, pp.1047~1054 (2007)
- Bataller R, "Liver fibrosis in alcoholic liver disease", Semin Liver Dis, 35, pp.146~156 (2015)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- De Ritis F, "An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities", Clin Chim Acta, 2, pp.70~74 (1957)
- Malhi H, "Cellular and molecular mechanisms of liver injury", Gastroenterology, 134, pp.1641~1654 (2008)
- Sgier C, "Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C", J Viral Hepat, 17, pp.845~850 (2010)
- Macdonald S, "Cell death markers in patients with cirrhosis and acute decompensation", Hepatology, 67, pp.989~1002 (2018)
- Guldiken N, "Keratins 8 and 18 are type II acute-phase responsive genes overexpressed in human liver disease", Liver Int, 35, pp.1203~1212 (2015)
- Strnad P, "Keratin variants predispose to acute liver failure and adverse outcome : race and ethnic associations", Gastroenterology, 139, pp.828~835 (2010)
- Zhong B, "Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity", Hepatology, 50, pp.546~554 (2009)
- Woolbright BL, "Cell death and prognosis of mortality in alcoholic hepatitis patients using plasma keratin-18", Gene Expr, 17, pp.301~312 (2017)
- Bissonnette J, "A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis", Hepatology, 66, pp.555~563 (2017)